ANDA 213221, held by MPP Pharma. Clomipramine Hydrochloride.
As of Nov 18, 2026, ANDA 213221 (Clomipramine Hydrochloride), held by MPP Pharma, was first approved by FDA on Jun 22, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 22, 2020 | Original application | Approved | None posted |
| Clomipramine Hydrochloride25MG · capsule;oral | Clomipramine Hydrochloride | Discontinued |
| Clomipramine Hydrochloride50MG · capsule;oral | Clomipramine Hydrochloride | Discontinued |
| Clomipramine Hydrochloride75MG · capsule;oral | Clomipramine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters